Process for hydrogenating aromatic compounds over a solid catalyst in the presence of a hydrogen-containing gas comprising a first reactor operated in loop mode, a second reactor operated in straight pass, at least part of the output of the first reactor is supplied to the second reactor, characterized in that the first reactor is configured as a trickle bed reactor and is operated in trickle bed mode and the second reactor is operated such that the catalyst present therein is partially flooded.

Process for hydrogenating aromatic compounds over a solid catalyst in the presence of a hydrogen-containing gas comprising a first reactor operated in loop mode, a second reactor operated in straight pass, at least part of the output of the first reactor is supplied to the second reactor, characterized in that the first reactor is configured as a trickle bed reactor and is operated in trickle bed mode and the second reactor is operated such that the catalyst present therein is partially flooded.

An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound. ##STR00001##

The invention relates to fused cyclooctyne compounds, and to a method for their preparation. The invention also relates to a conjugate wherein a fused cyclooctyne compound according to the invention is conjugated to a label, and to the use of these conjugates in bioorthogonal labeling, imaging and/or modification, such as for example surface modification, of a target molecule. The invention further relates to a method for the modification of a target molecule, wherein a conjugate according to the invention is reacted with a compound comprising a 1,3-dipole or a 1,3-(hetero)diene.

The invention relates to fused cyclooctyne compounds, and to a method for their preparation. The invention also relates to a conjugate wherein a fused cyclooctyne compound according to the invention is conjugated to a label, and to the use of these conjugates in bioorthogonal labeling, imaging and/or modification, such as for example surface modification, of a target molecule. The invention further relates to a method for the modification of a target molecule, wherein a conjugate according to the invention is reacted with a compound comprising a 1,3-dipole or a 1,3-(hetero)diene.

The present disclosure relates to methods of carbon-carbon bond fragmentation.

The present disclosure relates to methods of carbon-carbon bond fragmentation.

The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, said compound having the structure: Formula (I) ##STR00001##

The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, said compound having the structure: Formula (I) ##STR00001##

Provided is a compound which is capable of reducing a tilt angle of a liquid crystal molecule, and a polymerizable composition, a cured product, an optical film, a polarizing plate, and an image display device, each using the compound. The compound is represented, for example, by Formula (I), P-Sp-Z-G.sup.1-(X.sup.1-Cy.sup.1)n-(X.sup.2-A.sup.1)m-X.sup.3-A.sup.2.